| MRNA Snapshot | |
|---|---|
| Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts. | |
| VALUATION DATA | |
| Market Capitalization | $2,025 | Price to Sales | 4.00 |
| Earnings per Share | $0.0000 |
| PE Ratio | -3064999936 |
| PRICE DATA | |
| Most Recent Close | $24.3100 |
| 52 Week High | $32.47 |
| 52 Week Low | $3.073 |
| 50-Day Moving Average | $1.013 |
| 200-Day Moving Average | $1.679 |
| All data are from Alpha Vantage as of today. For more infomation on MRNA see Stock Dividend, Valuation, Price and Financial Data for Investors | |
Custom Search